RJA
HBIO icon

Raymond James & Associates’s Harvard Bioscience HBIO Stock Holding History

Raymond James & Associates’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,402
Closed -$240K – 4179
2021
Q4 		$240K Buy
+3,402
New +$242K ﹤0.01% 3582
2021
Q3 		– Sell
-3,377
Closed -$281K – 4181
2021
Q2 		$281K Buy
+3,377
New +$239K ﹤0.01% 3479
2021
Q1 		– Sell
-2,175
Closed -$93K – 4046
2020
Q4 		$93K Buy
+2,175
New +$81.2K ﹤0.01% 3567

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Raymond James & Associates's HBIO Position: Q1 2022 in Review

Raymond James & Associates sold out of Harvard Bioscience (HBIO) in Q1 2022, closing a stake of 3,402 shares — an estimated $240K sold.

Raymond James & Associates first reported a position in HBIO in Q4 2020 and held it in 3 quarters. The position peaked at $281K in Q2 2021. 98 funds tracked by Wall St. Rank hold HBIO as of Q1 2022.

  • Raymond James & Associates reported no remaining Harvard Bioscience position as of Q1 2022 after selling out during the quarter.
  • Raymond James & Associates sold 3,402 Harvard Bioscience shares in Q1 2022, an estimated $240K.
  • Raymond James & Associates first reported a position in Harvard Bioscience in Q4 2020 and held it in 3 quarters.
  • Raymond James & Associates's Harvard Bioscience position peaked at $281K in Q2 2021.
  • 98 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.